Show simple item record

dc.contributor.authorSahin, Ziver
dc.contributor.authorBıcakcıgil, Muge
dc.contributor.authorAksu, Kenan
dc.contributor.authorKamali, Sevil
dc.contributor.authorAkar, Servet
dc.contributor.authorOnen, Fatos
dc.contributor.authorKaradag, Omer
dc.contributor.authorOzbalkan, Zeynep
dc.contributor.authorAtes, Askin
dc.contributor.authorOzer, Huseyin TE
dc.contributor.authorYilmaz, Vuslat
dc.contributor.authorSeyahi, Emire
dc.contributor.authorOzturk, Mehmet A
dc.contributor.authorCefle, Ayse
dc.contributor.authorCobankara, Veli
dc.contributor.authorOnat, A Mesut
dc.contributor.authorTunc, Ercan
dc.contributor.authorDüzgün, Nursen
dc.contributor.authorAydin, Sibel Z
dc.contributor.authorYilmaz, Neslihan
dc.contributor.authorFresko, İzzet
dc.contributor.authorKaraaslan, Yasar
dc.contributor.authorKiraz, Sedat
dc.contributor.authorAkkoc, Nurullah
dc.contributor.authorInanc, Murat
dc.contributor.authorKeser, Gokhan
dc.contributor.authorUyar, F Aytul
dc.contributor.authorDireskeneli, Haner
dc.contributor.authorSaruhan-Direskeneli, Güher
dc.date.accessioned2019-12-19T07:02:46Z
dc.date.available2019-12-19T07:02:46Z
dc.date.issued2012
dc.identifier.issn1478-6354
dc.identifier.urihttps://doi.org/10.1186/ar3730
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392822/
dc.identifier.urihttp://hdl.handle.net/11655/20852
dc.description.abstractIntroduction HLA-B*51 and HLA-B*52 are two close human leukocyte antigen (HLA) allele groups with minor amino acid differences. However, they are associated with two different vasculitides (HLA-B*51 in Behçet's disease and HLA-B*52 in Takayasu's arteritis (TAK)) and with major clinical and immunological differences. In this study, we aimed to screen a large cohort of TAK patients from Turkey for the presence of HLA-B*51 and HLA-B*52 as susceptibility and severity factors. Methods TAK patients (n = 330) followed at a total of 15 centers were included in the study. The mean age of the patients was 37.8 years, and 86% were women. DNA samples from the patients and healthy controls (HC; n = 210) were isolated, and the presence of HLA-B*51 or HLA-B*52 was screened for by using PCR with sequence-specific primers. Results We found a significant association of HLA-B*52 with TAK (20.9% vs HC = 6.7%, P = 0.000, OR = 3.7, 95% CI = 2.02 to 6.77). The distribution of HLA-B*51 did not differ between TAK patients and HCs (22.7% vs 24.8%, OR = 0.9, 95% CI = 0.60 to 1.34). The presence of HLA-B*52 decreased in late-onset patients (> 40 years of age; 12.0%, P = 0.024, OR = 0.43, 95% CI = 0.20 to 0.91). Patients with angiographic type I disease with limited aortic involvement also had a lower presence of HLA-B*52 compared to those with all other disease subtypes (13.1% vs 26%, P = 0.005, OR = 0.43, 95% CI = 0.23 to 0.78). Conclusions In this study, the previously reported association of TAK with HLA-B*52 in other populations was confirmed in patients from Turkey. The functional relevance of HLA-B*52 in TAK pathogenesis needs to be explored further.
dc.relation.isversionof10.1186/ar3730
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleTakayasu'S Arteritis is Associated with Hla-B*52, but not with Hla-B*51, in Turkey
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion
dc.relation.journalArthritis Research & Therapy
dc.contributor.departmentFizyoterapi ve Rehabilitasyon
dc.identifier.volume14
dc.identifier.issue1
dc.identifier.startpageR27
dc.description.indexPubMed
dc.description.indexWoS
dc.description.indexScopus


Files in this item

This item appears in the following Collection(s)

Show simple item record